Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) of the thymus is reported to have characteristic features that distinguish it from MALT lymphoma of other organs; it is proposed to be a distinct clinicopathological subgroup of MALT lymphoma. We herein present a case of thymic MALT lymphoma accompanied by Sjögren's syndrome, involving the first report of a thymic MALT lymphoma patient carrying a chromosomal abnormality of 8q24. No c-myc gene translocation or c-Myc protein overexpression was observed, suggesting that c-myc was not involved in lymphomagenesis or progression. Although we did not examine the mechanisms by which the lymphoma developed, this chromosomal structural change in 8q24 may be associated with the pathogenesis in our case.
Introduction
Extranodal marginal zone lymphoma of mucosaassociated lymphoid tissue (MALT lymphoma) is a lowgrade B-cell lymphoma arising from various organs, such as the stomach, salivary gland, lung, head and neck, ocular adnexa, skin, thyroid gland and breast (1) , and is often associated with chronic inflammation and autoimmune diseases. Chromosomal abnormalities, such as trisomy 3, trisomy 18 or t(11;18)(q21;q21), are frequently seen in patients with MALT lymphoma. MALT lymphoma of the thymus, first reported by Isaacson et al. in 1990 (2) , is a rare subtype, of which around only 50 cases have been reported. In 2002, Inagaki et al. investigated 15 cases of thymic MALT lymphoma and showed that it is a distinct clinicopathological subgroup of MALT lymphoma, characterized by a predominance in Asia, marked predominance in women, strong association with autoimmune diseases, especially Sjögren's syndrome, epithelium-lined cysts, the presence of neoplastic plasma cells of the IgA phenotype and the absence of t(11;18)(q21;q21) (3). However, there are only a few reports of chromosomal abnormalities in cases of thymic MALT lymphoma and it has not been studied in detail. We herein present for the first time a case of thymic MALT lymphoma in a patient carrying a chromosomal abnormality of 8q24, which showed no c-myc gene translocation or c-Myc protein overexpression. This chromosomal aberration may be involved in the pathogenesis in our case. (Table) . An anterior mediastinal mass, measuring 30×20 mm in diameter (Fig. 1) , and features of interstitial pneumonia in the left lower lobe were noted on computed tomography, and gallium-67 citrate scintigraphy showed an increased uptake in the anterior mediastinal mass. No other regions with an abnormally intense uptake were found (Fig. 2) .
Mediastinal tumor resection, thymectomy and partial pneumonectomy of the left lower lobe were performed for a diagnosis. Histologically, monocytoid cells with centrocytelike cells diffusely infiltrating the thymus, with disruption of the epithelium, were apparent on AE1/AE3 immunostaining ( Fig. 3a, b) . The infiltrating cells were positive for CD20, CD79a and BCL-2. On immunohistochemical studies, IgA was predominantly positive in neoplastic cells, with plasmacytic differentiation (Fig. 3c) . Light chain restriction for kappa light chain was also noted (Fig. 3d) . MIB-1 staining showed only a few positive cells and the MIB-1 labeling index was low, at almost 3% (Fig. 3e) . No proliferation of the large cell component was seen. The patient was finally diagnosed with MALT lymphoma of the thymus. The lung biopsy specimen exhibited histological characteristics of nonspecific interstitial pneumonia associated with collagenvascular disease with no lymphoma involvement. Since no lymphoma lesions other than that in the thymus were found, we regarded the thymus as the primary site.
A G-banding chromosome analysis revealed that the lymphoma cells carried the chromosome abnormality 46,XX,add (8)(q24.1) [4] /46,XX [1] (Fig. 4a) . To detect c-myc geneassociated translocation, a fluorescence in situ hybridization (FISH) analysis was performed using a dual-color split probe. Split signals were detected in only 11 out of 1,000 cells, equal to the value of the negative control (Fig. 4b) . The copy number of c-myc was also normal. Immunohistochemical staining for c-Myc proteins showed that the tumor cells were negative for c-Myc (Fig. 3f) .
Because the left supraclavicular lymph nodes became enlarged to up to 15 mm in diameter after mediastinal tumor resection, the patient was treated with six courses of R-CVP (rituximab, cyclophosphamide, vincristine and prednisolone) and achieved complete remission (CR). She has maintained CR for more than one year.
Discussion
MALT lymphoma of the thymus is suggested to have characteristic features that distinguish it from MALT lymphoma of other organs, as reported by Inagaki et al. (3) . Our case also involved the typical features of thymic MALT lymphoma: occurrence in an Asian woman, the presence of underlying Sjögren's syndrome and the IgA-kappa phenotype histologically. Several chromosomal abnormalities have been identified in patients with non-thymic MALT lymphoma, including t(11;18)(q21;q21), t(3;14)(q27;q32), t(1; 14)(p22;q32)and t(14;18)(q32;q21), trisomies of chromosomes 3, 7, 12 and 18 and structural anomalies with breakpoints in 1q21 and 1p34 (4) . In cases of thymic MALT lymphoma, trisomy 3 (5-7) and trisomy 18 (5, 6, 8) have been reported using FISH analyses, but not MALT1-associated or IGH-associated translocation, including t(11;18) forming the API2-MALT1 fusion using karyotyping, FISH and reversetranscription polymerase chain reaction (RT-PCR) methods (3, 5, 9, 10). Moreover, only two cases of thymic MALT lymphoma showing abnormal karyotypes with Gbanding have been reported: 46,X,dup(X)(p11p22) (11) and trisomy 18 (12) . Another case involved a normal karyotype (13). Our case showed add(8)(q24.1); this is the first report of thymic MALT lymphoma associated with cytogenetic alteration of the 8q24 lesion. However, the c-myc gene, located on chromosome 8q24 and known to be involved in Burkitt's lymphoma and an aggressive phenotype of B-cell lymphomas, was not found to be translocated on the FISH analysis. We also showed that there was no overexpression of c-Myc protein in the neoplastic cells, and, histologically, no large cell component of lymphoma cells was evident. The low MIB-1 labeling index was also consistent with the lack of aggressive transformation of MALT lymphoma, probably caused by c-myc translocation and c-Myc protein overexpression. We thus speculate that c-myc was not involved in lymphomagenesis or progression in our case.
Chinen et al. analyzed 8q24 amplicons with double minute chromosomes in patient-derived acute myelogenous leukemia (AML) cells and an AML cell line, namely, HL60. They discovered fusion transcripts between PVT-1 (8q24.21) and NSMCE2 (8q24.13), and a fusion gene between NSMCE2 (8q24.13) and CCDC26 (8q24.21) (14) . PVT-1 encodes a long non-coding RNA and maps to chromosome 8q24. Some cases of Burkitt's lymphoma with translocation (2;8) or (8;22) have been indicated to involve translocation of PVT-1 (15) . PVT-1 amplification has been reported in ovarian cancer, breast cancer, colorectal cancer and hepatocellular carcinoma (16) (17) (18) , and it has been suggested that PVT-1 serves as an anti-apoptotic phenotype in studies of ovarian cancer, breast cancer and colorectal cancer cell lines (16, 17) . Genes except for c-myc on 8q24, such as PVT-1, might be candidates for contributors to the development of thymic MALT lymphoma. Disappointingly, we were unable to examine more details of genetic alterations, including PVT-1. Kominato et al. suggested that the numerical chromosome abnormality of trisomy 3, detected in 7/14 (50%) of patients in their study, might be associated with thymic MALT lymphoma development; however, no significant differences in the clinicopathological features were found between the patients with or without trisomy 3 (5). Candidate genes responsible for the development of thymic MALT lymphoma have not been identified. Although we did not examine the mechanisms by which lymphoma developed in the current case, this chromosomal structural change in 8q24 may be associated with the pathogenesis in our patient. Further studies to clarify these points will be needed in the future.
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